Get started
Author

Zhenlei Zhang

Designing anticancer copper(II) complexes by optimizing 2-pyridine-thiosemicarbazone ligands
2018 · Jungang Deng, Ping Yu, et al. · European Journal of Medicinal Chemistry · 91
Developing a Copper(II) Agent Based on His-146 and His-242 Residues of Human Serum Albumin Nanoparticles: Integration To Overcome Cisplatin Resistance and Inhibit the Metastasis of Nonsmall Cell Lung Cancer
2022 · Ming Jiang, Zhenlei Zhang, et al. · Journal of Medicinal Chemistry · 71
Designing a Mitochondria-Targeted Theranostic Cyclometalated Iridium(III) Complex: Overcoming Cisplatin Resistance and Inhibiting Tumor Metastasis through Necroptosis and Immune Response
2024 · Wenjuan Li, Ting Li, et al. · Journal of Medicinal Chemistry · 64
Developing an Anticancer Platinum(II) Compound Based on the Uniqueness of Human Serum Albumin
2023 · Zhenlei Zhang, Juzheng Zhang, et al. · Journal of Medicinal Chemistry · 63
Anticancer and biological properties of a Zn-2,6-diacetylpyridine bis(thiosemicarbazone) complex
2019 · Ping Yu, Jungang Deng, et al. · Metallomics · 52
Developing a Novel Gold(III) Agent to Treat Glioma Based on the Unique Properties of Apoferritin Nanoparticles: Inducing Lethal Autophagy and Apoptosis
2020 · Juzheng Zhang, Zhenlei Zhang, et al. · Journal of Medicinal Chemistry · 50
Current status of iridium-based complexes against lung cancer
2022 · Tongfu Yang, Minghui Zhu, et al. · Frontiers in Pharmacology · 49
PDF
Developing a Multitargeted Anticancer Palladium(II) Agent Based on the His-242 Residue in the IIA Subdomain of Human Serum Albumin
2023 · Wenjuan Li, Shanhe Li, et al. · Journal of Medicinal Chemistry · 48
Developing a Gadolinium(III) Compound Based on Apoferritin for Targeted Magnetic Resonance Imaging and Dual-Modal Therapy of Cancer
2023 · Xueyu Man, Tongfu Yang, et al. · Journal of Medicinal Chemistry · 47
Developing an Anticancer Copper(II) Multitarget Pro-Drug Based on the His146 Residue in the IB Subdomain of Modified Human Serum Albumin
2018 · Jun Wang, Yi Gou, et al. · Molecular Pharmaceutics · 46
Developing a Ruthenium(III) Complex to Trigger Gasdermin E-Mediated Pyroptosis and an Immune Response Based on Decitabine and Liposomes: Targeting Inhibition of Gastric Tumor Growth and Metastasis
2023 · Wenjuan Li, Shanhe Li, et al. · Journal of Medicinal Chemistry · 41
Developing a Novel Anticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy
2021 · Juzheng Zhang, Ming Jiang, et al. · Journal of Medicinal Chemistry · 38
Novel Brain-Tumor-Inhibiting Copper(II) Compound Based on a Human Serum Albumin (HSA)-Cell Penetrating Peptide Conjugate
2019 · Zhenlei Zhang, Ping Yu, et al. · Journal of Medicinal Chemistry · 38
Developing a Gallium(III) Agent Based on the Properties of the Tumor Microenvironment and Lactoferrin: Achieving Two-Agent Co-delivery and Multi-targeted Combination Therapy of Cancer
2022 · Tongfu Yang, Zhenlei Zhang, et al. · Journal of Medicinal Chemistry · 37
Developing a Novel Indium(III) Agent Based on Liposomes to Overcome Cisplatin-Induced Resistance in Breast Cancer by Multitargeting the Tumor Microenvironment Components
2021 · Ming Jiang, Yong Chu, et al. · Journal of Medicinal Chemistry · 37
HSA-based multi-target combination therapy: regulating drugs’ release from HSA and overcoming single drug resistance in a breast cancer model
2018 · Yi Gou, Zhenlei Zhang, et al. · Drug Delivery · 37
Four copper(II) compounds synthesized by anion regulation: Structure, anticancer function and anticancer mechanism
2016 · Zhenlei Zhang, Yi Gou, et al. · European Journal of Medicinal Chemistry · 36
Developing a Novel Indium(III) Agent Based on Human Serum Albumin Nanoparticles: Integrating Bioimaging and Therapy
2022 · Zhenlei Zhang, Tongfu Yang, et al. · Journal of Medicinal Chemistry · 34
Developing a Copper(II) Isopropyl 2-Pyridyl Ketone Thiosemicarbazone Compound Based on the IB Subdomain of Human Serum Albumin–Indomethacin Complex: Inhibiting Tumor Growth by Remodeling the Tumor Microenvironment
2024 · Xueyu Man, Shanhe Li, et al. · Journal of Medicinal Chemistry · 31
Development of a High-Efficacy and Low-Toxicity Cobalt(II) Agent for Targeting Inhibition of Tumor Growth through Mitochondrial Damage-Mediated Chemotherapy and Immunotherapy
2025 · Minghui Zhu, Shihang Xu, et al. · Journal of Medicinal Chemistry · 29
Developing a Rhodium(III) Complex to Reprogram the Tumor Immune and Metabolic Microenvironments: Overcoming Multidrug Resistance and Metastasis in Non-Small Cell Lung Cancer
2024 · Wenjuan Li, Shanhe Li, et al. · Journal of Medicinal Chemistry · 28
Developing a Palladium(II) Agent to Overcome Multidrug Resistance and Metastasis of Liver Tumor by Targeted Multiacting on Tumor Cell, Inactivating Cancer-Associated Fibroblast and Activating Immune Response
2024 · Ming Jiang, Wenjuan Li, et al. · Journal of Medicinal Chemistry · 28
Design of an Anticancer Copper(II) Prodrug Based on the Lys199 Residue of the Active Targeting Human Serum Albumin Nanoparticle Carrier
2017 · Yi Gou, Yao Zhang, et al. · Molecular Pharmaceutics · 27
Human Serum Albumin-Based Dual-Agent Delivery Systems for Combination Therapy: Acting against Cancer Cells and Inhibiting Neovascularization in the Tumor Microenvironment
2020 · Zhenlei Zhang, Juzheng Zhang, et al. · Molecular Pharmaceutics · 24
Novel Pt( ii ) complexes with modified aroyl-hydrazone Schiff-base ligands: synthesis, cytotoxicity and action mechanism
2019 · Jungang Deng, Ping Yu, et al. · Metallomics · 24
Works count: 83
Citation count: 1,243
H-index: 24
I10-index: 34
Year
Topic
Type